MYDECINE

News & Media

Mydecine Innovations Group Receives Shareholder and Court Approval for Spin-Out of Cannabis Subsidiaries

September 24, 2021
Mydecine shareholders voted 99.939% in favour of approving the Arrangement and received final approval of the Supreme Court of British Columbia.
Read More →

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

September 22, 2021
Patent pending formulation has the potential to further reduce patient anxiety as compared to pure psilocybin, when used in therapy or medical practice.
Read More →

Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

September 7, 2021
Dr. Matthew Johnson will lead research to look at the science and efficacy of MYCO-001 for the treatment of smoking cessation and nicotine dependence.
Read More →

Mydecine Innovations Group Announces MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

September 7, 2021
Dr. Matthew Johnson will lead research to look at the science and efficacy of MYCO-001 for the treatment of smoking cessation and nicotine dependence.
Read More →

Mydecine to Participate in Upcoming Conferences in September 2021

September 2, 2021
CEO Josh Bartch will participate in three upcoming conferences in September: H.C. Wainwright, Oppenheimer and Maxim
Read More →

PART 1 and 2: COO Damon Michaels On Mydecine’s Collaboration With Johns Hopkins University

August 27, 2021
Partnering with such a revered institution is a significant reputational win for Mydecine Innovations.
Read More →

Study to Determine if Psychedelics Help to Quit Cigarette Smoking

August 20, 2021
Psychedelics could provide just the right push to overcome nicotine addiction patterns like smoking.
Read More →

Mydecine Innovations strikes five-year research agreement with John Hopkins University to study psychedelic therapies

August 18, 2021
Chief Scientific Officer Rob Roscow said the research agreement demonstrates Mydecine's commitment to advancing psychedelic medicine.
Read More →

Mydecine Innovations finishes 2Q with C$7M in cash after busy research period pinpoints four new lead drug candidates

August 16, 2021
CEO Joshua Bartach told investors the company made “groundbreaking progress” and discoveries in its psilocybin compound research and drug development program.
Read More →

Mydecine to Participate in Upcoming Investor Events in August 2021

July 28, 2021
CEO Josh Bartch to participate in BTIG Biotechnology Conference (Aug.9-10) and Canaccord Genuity’s 41st Annual Growth Conference (Aug. 10-12).
Read More →

Mydecine: Nature’s Medicine for Mental Health

July 22, 2021
BTV takes an inside look at how Mydecine and Mindleap Health are developing and commercializing innovative solutions for treating mental health problems.
Read More →

Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds

July 21, 2021
Filing is part of continued efforts to grow Mydecine's robust IP portfolio as the company consistently files for new patents that offer high potential to expand psychedelics for medical use.
Read More →

Mydecine Innovations Group (OTCMKTS:MYCOF) Stock Soars 65% in a Month: Now What?

July 19, 2021
DRP Gazette, which reports on news from the Wall Street Grapevine, says Mydecine is a stock that investors could do well to keep in their watch lists.
Read More →

Mydecine Innovations Group™️ Proactive One2One Virtual Forum - 15th July 2021

July 16, 2021
Mydecine CEO Josh Bartch gives an in-depth presentation and answers questions on Mydecine and the market opportunity.
Read More →

Mydecine Innovations Group Announces Launch of Mindleap Version 2.0

July 13, 2021
The digital health platform will provide the infrastructure to support the conscious and trustworthy adoption of psychedelics.
Read More →

Mydecine's Prospects Look Magical, Like A Mushroom

July 13, 2021
Seeking Alpha takes a deep dive look into Mydecine from an investment perspective and the market opportunity with psychedelic-assisted therapeutic solutions.
Read More →

Psychedelic Finance Interview with Damon Michaels, Director, COO, & Co-Founder

July 9, 2021
Michaels talks in-depth about his background, role at Mydecine and what the market opportunities the company is focused on.
Read More →

Mydecine CEO Josh Bartch Speaks on Psilocybin and Smoking Cessation

July 8, 2021
Josh Bartch, co-founder and CEO, discusses the possibility of Mydecine using the compounds MYCO-001 and 004 to enable smoking cessation.
Read More →

The Next Step for Legal Mushrooms—Losing the Trip

July 7, 2021
Bob Marley’s family and others are getting in on the non-psychedelic, CBD version of magic mushrooms.
Read More →

Mydecine: Innovative Solutions for Treating Mental Health

July 6, 2021
It‘s definitely an exciting time for Mydecine, with more positive coverage expected in the weeks and months ahead.
Read More →

Mydecine to launch Phase 2A clinical trial on psilocybin assisted psychotherapy to treat PTSD in veterans

June 25, 2021
CEO Joshua Bartch said the upcoming trial is aimed at achieving safer and more accurate psychedelic-led psychotherapy results in a supervised setting
Read More →

Mydecine selects substance use disorder and smoking cessation for its psychedelic molecule MYCO-004

June 24, 2021
MYCO-004 is a patch-delivered tryptamine compound and its properties include short duration, transdermal, precision dosing, and long-term compound stability.
Read More →

Mydecine Innovations Group (MYCOF) Stock Sees Double-Digit Rally: What Next?

June 23, 2021
The Mydecine stock was in the news after Roth Capital Partners started covering the stock and gave it a buy rating.
Read More →

Mydecine to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th

June 23, 2021
Mydecine CEO Josh Bartch will participate in the ROTH Healthcare Private Company Forum and speak on the panel titled Next Wave of Psychedelic Drug Developers.
Read More →

Meet Delic presents: MUSHROOMS, A Three-Part Series powered by Mydecine

June 23, 2021
Meet Delic LIVE virtual events provide free pyschedelic education to all as psychedelic wellness is for everyone.
Read More →

Roth Initiates Coverage On Mydecine Innovations With A 9x Price Target

June 23, 2021
Roth Capital Partners (RCP) bestowed an eye-opening price target that instantly captured the market’s attention.
Read More →

Mushroom Revival Podcast: Mydecine: Psilocybin Sciences

June 23, 2021
Josh Bartch, the CEO of Mydecine, discusses the origins of their work, their team, and current research and practices in the field.
Read More →

Roth Capital Partners Initiates Coverage on Mydecine

June 22, 2021
Mydecine is the first to treat PTSD and smoking cessation with the natural form of psilocybin (MYCO – 001).
Read More →

Mydecine Identifies 4 Psychedelic-Related Drugs to Tackle the Mental Health Crisis

June 17, 2021
The four psychedelic drugs can eliminate cardiovascular risk issues and significantly reduce the half-life to less than two hours.
Read More →

Mydecine Innovations kicks off machine learning-based drug discovery program with the University of Alberta

June 16, 2021
The program will enable the company to more rapidly screen hundreds of thousands of new molecules without the need to produce them.
Read More →

Mydecine Innovations Group Launches AI-Assisted Drug Discovery Program

June 16, 2021
The program will use artificial intelligence and machine learning to inform its drug discovery process.
Read More →

The Dales Report: Getting People to Help Changes Everything

June 11, 2021
William Cook, Interim CEO and Technical Director of the subsidiary company, MindLeap Health, talks about Version 2.0 of the MindLeap app launching soon.
Read More →

Mydecine Discovers Over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

June 8, 2021
A large majority appear to have never been reported before and could be vital to the critical effects of naturally-sourced mushrooms on human health and wellbeing.
Read More →

Mydecine to Participate in the H.C. Wainwright Psychedelics in Psychiatry and Beyond Conference

June 3, 2021
Mr. Bartch’s corporate presentation will be available on-demand starting at 7:00 a.m. ET on June 17.
Read More →

The Dales Report: Microdosing, PTSD and Research: Mydecine COO Damon Michaels Talks Psychedelics

June 3, 2021
Part II: Michaels talks about the addressable market for PTSD, how quickly the industry for psychedelics is moving, and how big pharma may get involved.
Read More →

Mydecine COO Damon Michaels on Canada Cultivation and Mushroom Editing

May 31, 2021
COO discusses the expansion of its cultivation facilities in Canada, the possibility of genetically editing mushrooms, and the roadmap for next 12 months.
Read More →

Mydecine wins Health Canada approval for expanding cultivation capabilities for psilocybin producing mushrooms

May 25, 2021
Chief Science Officer Rob Roscow said it will “enhance” the firm’s ability to “produce pharmaceutical-grade psilocybin at scale”
Read More →

Psychedelic Solutions: How Mydecine Innovations Group is Working to Solve the Mental Health Crisis

May 25, 2021
Mydecine Innovations Group is a key force driving this innovation and is bridging the gap between the two industries.
Read More →

Mydecine Provides Update on Spin-Out of U.S. Cannabis Assets

May 19, 2021
Company intends to spin off its U.S. cannabis assets and its interests in U.S. cannabis projects into a newly incorporated subsidiary (“SpinCo”).
Read More →

Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update

May 18, 2021
Strategic Partnerships Expand Drug Development Capabilities to More Efficiently and Rapidly Lead the Next Generation of Psychedelic-Assisted Therapeutics.
Read More →

Mydecine to Participate in the Benzinga Global Small Cap Conference on May 13th

May 10, 2021
Mydecine CEO Josh Bartch will speak on the panel titled Investing in the Mental Health Crisis Through Psychedelics.
Read More →

Mydecine CSO Rob Roscow Joins The Dales Report Podcast

May 6, 2021
Roscow talks Mydecine’s upcoming phase 2a clinical trials on psylocibin-assisted PTSD treatments, barriers presented by COVID, and the new novel drug candidates.
Read More →

Mydecine Announces Partnership with LeadGen Labs

May 5, 2021
LeadGen Labs partnership will considerably increase Mydecine’s synthesis capabilities of novel molecules.
Read More →

Mydecine Reports Full Year 2020 Financial Results and Provides Business Update

May 3, 2021
Strengthened Balance Sheet with Approximately $30 Million in Capital Raised Subsequent to the Year-End.
Read More →

Mydecine Innovations Group Inc. (MYCOF) CEO Josh Bartch on Q4 2020 Results - Earnings Call Transcript

May 3, 2021
Participants include Josh Bartch - Co-founder, Chairman and CEO; Dean Ditto - Chief Financial Officer; and Allison Soss - Investor Relations.
Read More →

Mydecine Innovations Group’s Joshua Bartch joins the Psychedelic Spotlight podcast

April 28, 2021
Podcast discusses the company's novel research protocols, its relationship with legal psilocybin growers in Jamaica, and the future for psychedelic therapy.‍
Read More →

Mydecine to Report Full Year 2020 Financial Results on May 3, 2021

April 26, 2021
Company will host a conference call and audio webcast that morning at 10:30 a.m. ET featuring remarks by Josh Bartch, CEO and Dean Ditto, CFO.
Read More →

Biotech Companies Driving Psychedelics Industry Forward with Key Research

April 13, 2021
Mydecine and other companies are looking into natural medicine initiatives to improve the quality of life of individuals struggling with mental health disorders.
Read More →

Mydecine Announces Launch of Cutting-Edge Therapeutic Compound Screening

April 13, 2021
Move represents next steps in company's research and development process as it investigates the chemical compounds and potential therapeutic effects of natural psilocybin.
Read More →

Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical

April 7, 2021
Mydecine believes that these drug candidates are unique and patentable in the United States and Canada.
Read More →

Psychedelic Experience ‘Promising’ in Treating PTSD – Mydecine CMO Dr. Rakesh Jetly

March 30, 2021
Podcast discusses how the psychedelic experience is key to treating PTSD and how it may teach us about how psychedelics make the brain open to new ideas.
Read More →

Mydecine Innovations Group Graduates Listing To NEO Exchange

March 23, 2021
Fast growing biotech company becomes latest in a wave of migrations and graduations to the NEO Exchange.
Read More →

CSO Rob Roscow: Transforming Research From Mydecine’s 3 Pillars Into Repeatable Medicine

March 23, 2021
Shadd Dales talks with Mydecine Innovations Chief Science Officer Rob Roscow about Mydecine’s three main operational pillars: IP/R&D, Clinical Trials and Technology.
Read More →

What are your favorite publicly traded companies in the psychedelic sector?

March 19, 2021
Vote for the public companies that are leading the emergence of psychedelics as a form of mental health treatment.
Read More →

Mydecine CEO Josh Bartch on the Future of Psychedelics

March 18, 2021
With recent landmark progress in legalization efforts around the world, it’s clear we are in a psychedelic renaissance.
Read More →

The Window of Opportunity is Here

March 18, 2021
­In depth look at how psychedelic mental health solutions are gaining steam with elite athletes and researchers.
Read More →

Mydecine Innovations Group Provides Update on European Operations

March 16, 2021
Mydecine appoints former Novartis Norway CEO Michel Rudolphie as President of European Operations and partners with Dr. David Erritzoe for research.
Read More →

Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.] Cannabis Asset

March 10, 2021
Mydecine’s principal business will focus on the development and commercialization of solutions for treating mental health problems through its psilocybin research and development.
Read More →

Mydecine Co-Founder Damon Michaels: It’s Time To Make Alternative Medicine Modern Medicine

March 9, 2021
The chief operating officer sat down with The Dales Report last week to discuss the company’s latest activity.
Read More →

Mydecine Innovations’ Josh Bartch: The Last 12 Months Have Been Monumental For The Industry

March 4, 2021
Josh Bartch, Co-Founder & CEO of Mydecine, talks to Shadd Dales of The Dales Report to put recent company events in context.
Read More →

Mydecine Innovations Group cultivating low-cost psilocybin mushrooms at scale to treat PTSD

March 4, 2021
CEO Joshua Bartch tells Proactive the Colorado-based emerging biotech and life sciences company is making tremendous advancements.
Read More →

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain

March 1, 2021
Milestone means Mydecine is now able to access a quality source of product for research purposes and to sell and transfer to other licensed global research facilities.
Read More →

Mydecine Innovations: Unlocking Fungi’s Pharmacological and Nutraceutical Healing Properties

March 1, 2021
The Dales Report takes a look at Mydecine Innovations Group and its position in the world of early-stage psychedelic investing.
Read More →

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

February 24, 2021
Partnership Supports Mydecine’s Drug Development and Clinical Trials Pipeline; Provides Update on Debt Settlement.
Read More →

Behind the World-First Export of Jamaican Psilocybin Mushrooms

February 19, 2021
Mydecine’s Chief Scientific Officer and Co-Founder Rob Roscow talks first harvest and commercial export of legal psychedelic psilocybin mushrooms.
Read More →

Truffle Talk with Joshua Bartch of Mydecine Innovations Group

February 18, 2021
Co-founder and CEO Joshua Bartch speaks to Truffle Report about the company’s psychedelics research program.
Read More →

Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap’s Mental Health Technolog

February 17, 2021
Digital health platform will combine telemedicine, on-demand mental health programs and advanced wellbeing analytics.
Read More →

Mydecine Innovations Group Partners with Microdose to Present a Webinar on Psychedelic Drug Development

February 16, 2021
Mydecine panelists will discuss if Psychedelic Drug Design can Improve Safety and Efficacy for Medicine.
Read More →

Magic mushroom therapy could help treat PTSD in Canadian military vets

February 16, 2021
Mydecine's Chief Medical Officer offers a few hypotheses as to why PTSD in veterans can be difficult to treat.
Read More →

Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

February 12, 2021
Offering further strengthens Mydecine’s balance sheet and positions the Company for continued growth in 2021.
Read More →

The Current Status of Psychedelics in Psychiatry

February 4, 2021
Mydecine Innovations Group Advisory Board Member Robin Carhart-Harris, PhD and David Nutt, MD, PhD provide viewpoint on industry progress.
Read More →

Mydecine Innovations Group Appoints Josephine Wu to Board of Directors

February 3, 2021
Wu brings in an extensive network of experts in operation, clinical, market positioning and regulatory knowledge in the Pan Asia healthcare landscape.
Read More →

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange

February 1, 2021
With the move, the company is positioning its common shares to be traded on a senior exchange in Canada, providing exposure to more investors.
Read More →

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland

January 28, 2021
The research goal is to get a better understanding of when, where and how psilocybin is most appropriate for use in human therapeutics.
Read More →

Mydecine Innovations Group Files Application to list to the NASDAQ

January 27, 2021
Mydecine submitted a formal application to list its common shares on the second largest exchange by market capitalization worldwide.
Read More →

Research and Development Moves the Psychedelics Market Forward

January 27, 2021
FN Media Group presents Microsmallcap.com market commentary on the companies that are commercializing psychedelic medicines.
Read More →

Microdosing Mysteries: The New Science Exploring Tiny Doses of Psychedelics

January 24, 2021
New Atlas's Flipboard aggregates some of the top stories from around the world on the subject of psychedelics.
Read More →

Mydecine Innovations Group Included in First-Ever Psychedelics ETF

January 22, 2021
Mydecine is one of 17 companies to be included in the Horizons Psychedelic Stock Index Exchanged Traded Fund (ETF).
Read More →

Mydecine Innovations Group Files Preliminary Prospectus

January 21, 2021
Prospectus filing is in connection with its bought deal offering previously announced on January 14, 2021.
Read More →

Mydecine Co-founder and CEO sees a big future for psilocybin and other mushroom-based compounds

January 17, 2021
Josh Bartch highlights how Mydecine Innovations Group is well positioned in the pharmaceuticals and consumer packaged goods industries.
Read More →

Researchers will soon test psychosubstances as a potential treatment for veterans with PTSD.

January 14, 2021
Mydecine's Rakesh Jetly, MD joins HCPLive® to talk about how research is on the cutting edge of a breakthrough treating trauma.
Read More →

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

January 14, 2021
The emerging biopharma and life sciences company announces that it has entered into an agreement with Canaccord Genuity Corp.
Read More →

Mydecine Innovations Group Upsizes Previously Announced Bought Deal

January 14, 2021
Mydecine announces that it has agreed to increase the size of its previously announced bought deal financing led by Canaccord Genuity Corp.
Read More →

Mydecine Innovations Group Uniquely Positioned To Take Over 2021

January 13, 2021
Microdose Psychedelic Insights, which provides Psychedelic industry insight and market intelligence, believes the future is bright for Mydecine.
Read More →

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer

January 11, 2021
MYCO Continues to Strengthen Board of Directors in Anticipation of Senior Exchange Listing Requirements.
Read More →

As the Focus on Psychedelic Stocks Increases, So Do the Valuations

January 11, 2021
The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.
Read More →

5 Groovy Psychedelic Stocks to Buy

January 8, 2021
Investor Place reports that “The Times They Are A-Changin’” for psychedelic mental health treatments.
Read More →

Mydecine Innovations Group Shares Intellectual Property Update

January 7, 2021
Mydecine Innovations Group files seven provisional patent applications with United States Patent and Trademark Office.
Read More →

Further Research into Psilocybin Opens New Doors for Treatment

January 7, 2021
Financial Buzz highlights five companies, including Mydecine Innovations Group, that are leading research efforts into Psilocybin.
Read More →

2020 Was A Year of Historic Firsts That Set the Stage for the Psychedelic Renaissance

January 6, 2021
Microdose Psychedelic Insights breaks down all the psychedelic industry advancements made in the year 2020.
Read More →

Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia

January 5, 2021
Study will also be the first to use Magnetoencephalography, or MEG scans, to identify brain activity, along with planned cognitive and biometric measures, while microdosing.
Read More →

The Year In Review For Psychedelic Drug Stocks: 2020

December 23, 2020
Multi-bagger returns for several companies; Large and rising capital flows into the industry; Very favorable media coverage and public opinion.
Read More →

Psychedelic Scientist Robin Carhart Harris Leads The Research Renaissance With Over 100 Peer-Reviewed Publications

December 23, 2020
Highlighting notable scientific achievements Harris has made towards advancing the psychedelic renaissance.
Read More →

Psychedelics Industry Gearing Up For an Even Bigger 2021

December 21, 2020
Mydecine Innovations Group is focused on developing and commercializing innovative solutions to treat mental health problems and enhance well being.
Read More →

Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials

December 21, 2020
Mydecine has engaged ethica CRO, a full-service Contract Research Organization (“CRO”) that conducts and manages ethical clinical research.
Read More →

Mydecine Speaker Series: Psychedelic Solutions

December 21, 2020
Mydecine panellists discuss psychedelic solutions in speaker series moderated by Business Insider journalist Yeji Lee.
Read More →

2020: A Year In Review for the Psychedelic Renaissance

December 20, 2020
The year 2020 has been a really big year for magic mushrooms and the fast-paced growth of psychedelic medicine.
Read More →

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

December 15, 2020
Leading FDA consultancy firm ProPharma Group to advise on drug development and clinical trial pipeline.
Read More →

Push for Alternative Therapies Prods Researchers Towards Psilocybin

December 15, 2020
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends, provides update on Mydecine.
Read More →

Mydecine to make first legal import of psilocybin mushrooms into Canada

December 11, 2020
Canada continues to open the door for clinical research the effectiveness of psilocybin for mental health treatments.
Read More →
← Back to homepage